Geriatria
Diretrizes antecipadas de vontade para pessoas com demência: reconhecimento dos dilemas morais enfrentados pelos médicos.
28 Mai, 2021 | 10:40hPessários para prolapso de órgão pélvico – Análise das evidências Cochrane.
24 Mai, 2021 | 10:45hPessaries for pelvic organ prolapse – looking at the Cochrane evidence – Evidently Cochrane
Revisão original: Pessaries (mechanical devices) for managing pelvic organ prolapse in women – Cochrane Library
Estudo randomizado: Quimioterapia de intensidade reduzida em pacientes idosos frágeis com câncer gastresofágico avançado propicia uma melhor experiência ao paciente, sem perda significativa no controle da doença.
20 Mai, 2021 | 10:42h
Comentário no Twitter
The GO2 trial tested reduced intensity of chemo for pts w adv gastroesophageal cancer & found reducing intensity led to comparable survival but w improved patient experience, & decision-making can be enhanced using geriatric assessment https://t.co/DtZOXcozo7 #GeriOnc
— JAMA Oncology (@JAMAOnc) May 13, 2021
#ACC21 – Estudo randomizado: Não há diferenças significativas em eventos cardiovasculares ou sangramento maior entre pacientes que recebem diariamente 81 mg vs. 325 mg de aspirina.
17 Mai, 2021 | 09:29hComparative Effectiveness of Aspirin Dosing in Cardiovascular Disease – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentários: High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE – TCTMD E Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness – ADAPTABLE – American College of Cardiology
Vídeo: Aspirin Dosing: A Patient-centric Trial Assessing Benefits And Long-term Effectiveness Trial
#ACC21 – Estudo randomizado: Programa de reabilitação precoce e personalizado para insuficiência cardíaca traz benefícios físicos e emocionais para pacientes idosos.
17 Mai, 2021 | 09:26hComentários: Tailored, earlier heart failure rehab has physical, emotional benefits for patients – National institutes of Health E REHAB-HF: Tailored Cardiac Rehab Program Improved Function and Quality of Life in Older HF Patients – American College of Cardiology E Rehabilitation Therapy in Older Acute Heart Failure Patients – REHAB-HF – American College of Cardiology
Comentários no Twitter
#REHAB-HF #ACC21 innovative intensive rehab improved physical function
-attention to SDOH environment assessment & involvement of family/care givers
-q2 wk trouble shooting discussion
-corrected balance/mobility first to get pts on treadmill w confidence https://t.co/rOmsc6qdq3 pic.twitter.com/V8TugBipUT— Ritu Thamman MD (@iamritu) May 16, 2021
REHAB-HF trial results found novel #CVRehab program tailored to address specific physical impairments in frail/older patients w/ acute #HeartFailure improved physical function & quality of life; did not significantly reduce hospitalizations. https://t.co/f98IdMvqj4 #ACC21 #cvGeri pic.twitter.com/zY8E1WBNmf
— American College of Cardiology (@ACCinTouch) May 16, 2021
2 metanálises recentes destacam os benefícios de dupla antiagragação plaquetária com clopidogrel + aspirina por até 30 dias para pacientes com ataque isquêmico transitório de alto risco ou AVC isquêmico leve-moderado.
17 Mai, 2021 | 09:21hMetanálise 2: Efficacy and Safety of Using Dual Versus Monotherapy Antiplatelet Agents in Secondary Stroke Prevention: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials – Circulation (link para o resumo – $ para o texto completo)
Comentário: Dual vs. Monotherapy Antiplatelet Agents in Secondary Stroke Prevention – American College of Cardiology
Diretriz relacionada: Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke – The BMJ
Cuidado desnecessário? 1 em 3 pacientes com demência avançada e fibrilação atrial ainda recebem anticoagulantes.
17 Mai, 2021 | 09:19hEstudo original: Anticoagulant Use for Atrial Fibrillation Among Persons With Advanced Dementia at the End of Life – JAMA Internal Medicine (gratuito por período limitado)
Editorial: Anticoagulation at the End of Life: Time for a Rational Framework (gratuito por período limitado)
Opinião | Como dar suporte para substitutos que tomam decisões médicas para pacientes criticamente doentes.
17 Mai, 2021 | 09:17hReconceptualizing How to Support Surrogates Making Medical Decisions for Critically Ill Patients – JAMA (gratuito por tempo limitado)
Polifarmácia, prescrição inadequada e “deprescribing” em idosos: sob a ótica de sexo e gênero.
14 Mai, 2021 | 10:00hPodcast com a autora: Dr Paula Rochon talks with The Lancet Healthy Longevity about polypharmacy in older people through a sex and gender lens
Relacionados: Reducing Inappropriate Medication Use & Polypharmacy (diversos artigos e comentários sobre o assunto) E Polypharmacy Management in Older Patients – Mayo Clinic Proceedings E Psychopharmacological Treatment in Older People: Avoiding Drug Interactions and Polypharmacy – Deutsches Ärzteblatt internationa E Eliminating Medication Overload: A National Action Plan E Deprescribing in Older Adults With Cardiovascular Disease – Journal of the American College of Cardiology
Comentário no Twitter
NEW REVIEW: @RochonPaula and colleagues look at #polypharmacy & #deprescribing for #older people through a sex & gender lens
👀Read the #openaccess paper here: https://t.co/CpcJswOtt1
👂Listen to the new podcast with the authors here:https://t.co/EXg9wNlE9K pic.twitter.com/AZ4VkKt33p— The Lancet Healthy Longevity (@LancetLongevity) May 13, 2021
M-A: Suplementação de ácidos graxos ômega-3 aumenta o risco de fibrilação atrial em pacientes com dislipidemia.
10 Mai, 2021 | 11:12hComentários: Fish oil supplements linked with heart rhythm disorder – European Society of Cardiology E Could High-Dose Fish Oil Raise Odds for A-Fib in Heart Patients? – HealthDay
Comentário no Twitter
Our latest work showing an increased risk of AFib with O3FA supplementation.
Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials https://t.co/7Z8CAuDHNr @totocarbone @gbiondizoccai @MarcoDelBuono3 pic.twitter.com/A5m77y5xTE
— Dave Dixon, PharmD (@DaveDixonPharmD) April 29, 2021